Related Experiment Video
Updated: Aug 13, 2026
09:50
Procedure for Human Saphenous Veins Ex Vivo Perfusion and External Reinforcement
Published on: October 1, 2014
Femoropopliteal bypass using autogenous vein and modified human umbilical vein. A comparative study
H J Parker1, G Fell, T J Devine
1Western General Hospital Vascular Unit, Melbourne, Australia.
The Journal of Cardiovascular Surgery
|November 1, 1988
Summary
Autogenous vein grafts show superior 5-year patency rates compared to modified human umbilical vein grafts for femoropopliteal bypass. However, modified human umbilical vein is a viable alternative when autogenous vein is unavailable.
Area of Science:
- Vascular Surgery
- Biomaterials in Surgery
Background:
- Femoro-popliteal and femorotibial bypass grafts are crucial for treating peripheral artery disease.
- Autogenous vein and modified human umbilical vein are common graft materials.
Purpose of the Study:
- To compare the long-term patency and limb salvage rates of autogenous vein versus modified human umbilical vein grafts.
- To evaluate graft performance based on anastomosis site and indication for surgery.
Main Methods:
- Retrospective analysis of 223 femoro-popliteal and femorotibial bypass grafts.
- Data collected from January 1978 to June 1985.
- Comparison of 5-year patency and limb salvage rates between graft types.
Main Results:
- Autogenous vein grafts had significantly higher 5-year patency rates (54%) than modified human umbilical vein (32%).
- This difference was more pronounced for below-knee anastomoses (56% vs. 26%).
- Similar 5-year patency rates were observed for grafts to superficial femoral artery and common femoral artery.
Conclusions:
- Autogenous vein grafts offer superior long-term patency for femoropopliteal bypass.
- Modified human umbilical vein demonstrates comparable efficacy to autogenous vein in cases of severe ischemia.
- Modified human umbilical vein serves as a suitable alternative when autogenous vein is not available.
